Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
The company’s massive clinical programme with BMS-986165 is set to deliver its first pivotal data later this year.
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Dupixent might face a threat to its lead in dermatitis – but this comes from Pfizer, not Leo.
With data from a head-to-head trial against Cosentyx due soon, UCB’s bimekizumab seeks to enter a crowded psoriasis market.